drugset / Trial / NCT04111497

Glasdegib for Chronic Graft-Versus-Host Disease

NCT04111497

Phase 1/2 Terminated 15 enrolled Fred Hutchinson Cancer Center Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease. It will also investigate the safety of glasdegib in treating patients with chronic graft-versus-host disease.

Timeline

Start
2019-12-03
Primary completion
2023-08-23
Completion
2023-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Glasdegib Small molecule Oral